02.09.2013 • News

Dow Confirms U.S. Sites for New Shale Gas-fed Plants

Dow Chemical has confirmed the locations for its planned new shale gas-fed polymer plants on the U.S. Gulf Coast, announced in March of this year and expected to be in full operation by 2017. The U.S. group said the new facilities expected to cost around $ 1 billion - along with other "high-return investments" in the region - have potential to deliver EBITDA of as much as $2.5 billion. Capacity numbers have not been disclosed.

Freeport, Texas, is the site selected for expansion of Dow's Affinity-brand high melt index polymers, used to strengthen the bonding properties of hot-melt packaging adhesives, as well as its Elite polymers for medical and packaging applications. Both plants will use the group's proprietary Insite catalyst technology.

Plaquemine, Louisiana, is the location chosen for the planned expansion of the metallocene-based Nordel-brand EPDM rubber facility, along with a new plant for high-performance LDPE food packaging grades such as the Agility brand.

Executive vice president Jim Fitterling said Dow will be further able to leverage its cost-advantaged position and R&D expertise to provide a competitive benefit for customers in "many of our most strategic markets."

The U.S. group's plans for capitalizing on the shale gas boom also include a 1.5 million t/y ethylene facility due to start up at Freeport in 2017 and a 750,000 t/y propane dehydrogenation plant expected to go on stream in 2015.

 

 

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.